Instruction for Spasgan Neo
You can buy Spasgan Neo on this page
Weak and moderate pain syndrome in spasms of smooth muscles of internal organs: renal and biliary colic, biliary dyskinesia, intestinal colic.
- Gynecological diseases: dysmenorrhea.
- Headache, including migraine nature.
- Short-term symptomatic treatment of pain in the joints, neuralgia, sciatica, myalgia.
Hypersensitivity to any of the ingredients that make up Spasgan Neo; erosive and ulcerative changes of the mucous membrane of the stomach or duodenum, active gastrointestinal bleeding; inflammatory bowel disease in the acute phase, including ulcerative colitis; anamnestic data on the attack of bronchial obstruction, rhinitis, urticaria, after taking acetylsalicylic acid or another nonsteroidal anti-inflammatory drug - NSAIDs (complete or incomplete intolerance syndrome acetylsalicylic acid - rhinosinusitis, urticaria, polyps of the nasal mucosa, bronchial asthma); liver failure or active liver disease; renal failure (creatinine clearance less than 30 ml / min), progressive kidney disease; confirmed hyperkalemia; hemophilia and other bleeding disorders including hypocoagulation), hemorrhagic diathesis; the period after coronary artery bypass surgery; acute intermittent porphyria; granulocytopenia; blood disorders; deficiency of glucose-6-phosphate dehydrogenase; tachyarrhythmia; angle-closure glaucoma; diseases of the optic nerve; prostatic hyperplasia; intestinal obstruction; pregnancy and breastfeeding period, age up to 16 years.
Older age, congestive heart failure, cerebrovascular diseases, arterial hypertension, coronary heart disease, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral artery disease, nephrotic syndrome, creatinine clearance less than 30-60 ml / min, hyperbilirubinemia, gastric ulcer, hyperilirophinemia, gastric ulcer, hypochilirubinemia, gastric ulcer, heart rate, 30 -60 ml / min, hyperbilirubinemia, gastric ulcer, hypochilirubinemia, gastric ulcer, less than 30-60 ml / minute in history), the presence of Helicobacter pylori infection, gastritis, enteritis, colitis, prolonged use of NSAIDs, blood diseases of unknown etiology (leukopenia, anemia), smoking, frequent use alcohol (alcohol), severe somatic diseases, concomitant therapy following drugs: anticoagulant (e.g., warfarin), antiplatelet agents (e.g., aspirin, clopidogrel), oral corticosteroids (e.g., prednisone), selective serotonin reuptake inhibitor (such as citalopram, fluoxetine , paroxetine, sertraline).
Pregnancy and lactation
The use of Spasgan Neo during pregnancy is contraindicated.
In the appointment of the drug during breastfeeding should decide on its termination.
Active substances: ibuprofen, pitofenone hydrochloride, fenpiverinium bromide.
Product form: tablets, film coated 400 mg + 5 mg + 0.1 mg No. 20.
Mode of application
Inside, 1 hour before or 3 hours after meals. In order to avoid irritating the stomach, you can take Spasgan Neo immediately after a meal or drink milk.
In the absence of specific medical prescriptions, it is recommended to take Spasgan NEO for spastic pains, 1 tablet up to 3 times a day. The maximum daily dose is 3 tablets. Do not exceed the specified dose!
The course of treatment with SPASGAN NEO, without consulting a doctor, should not exceed 5 days. A more prolonged use is possible under the supervision of a physician with monitoring indicators of the peripheral blood picture and the functional state of the liver.
In therapeutic doses, the drug SPASGAN NEO does not enter into significant interactions with widely used drugs.
The inducers of microsomal oxidation enzymes in the liver (phenytoin, ethanol, barbiturates, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites, increasing the risk of developing severe intoxications.
Inhibitors of microsomal oxidation reduce the risk of hepatotoxic action.
Reduces the hypotensive activity of vasodilators and the natriuretic effect of furosemide and hydrochlorothiazide.
Reduces the effectiveness of uricosuric drugs.
It enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics (which increases the risk of bleeding).
Strengthens the side effects of mineral corticosteroids, glucocorticosteroids (increases the risk of gastrointestinal bleeding), estrogen, ethanol.
With simultaneous use of Spasgan Neo with hypoglycemic agents for oral administration may enhance their effect, thereby contributing to the risk of hypoglycemia.
Antacids and colestyramine reduce the absorption of ibuprofen.
Increases blood concentration of digoxin, lithium preparations and methotrexate. Enhances the action of M-anticholinergics, H1-histamine blockers, butyrophenones, phenothiazines, amantadine and quinidine.
The simultaneous appointment of other NSAIDs increases the frequency of side effects.
Caffeine enhances the analgesic (analgesic) effect.
With the simultaneous appointment reduces the anti-inflammatory and antiplatelet effect of acetylsalicylic acid (it is possible to increase the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent, after starting the administration of SPASGAN NEO.
Cefamendol, cefaperazon, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia with simultaneous appointment.
Myelotoxic drugs increase the hematotoxicity of Spasgan Neo.
Cyclosporine and gold preparations enhance the effect of ibuprofen on the synthesis of prostaglandins in the kidneys, which is manifested by an increase in nephrotoxicity. Ibuprofen increases the plasma concentration of cyclosporine and the likelihood of its hepatotoxic effects.
Drugs that block tubular secretion, reduce excretion and increase the plasma concentration of ibuprofen.
Side effects of Spasgan Neo
The frequency of side effects is classified according to the recommendations of the World Health Organization: characterized as very often - at least 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0.1%, but less than 1%; rarely - not less than 0.01%, but less than <0.1%; very rarely, including individual messages - less than 0.01%.
In recommended doses, SPASGAN NEO does not cause side effects.
On the part of the digestive system: often - NSAID gastropathy (abdominal pain, nausea, vomiting, heartburn, loss of appetite, diarrhea, flatulence, constipation; rarely - ulceration of the mucous membrane of the gastrointestinal tract, which, in some cases, are complicated by perforation and bleeding; irritation and dryness of the oral mucosa, pain in the mouth, ulceration of the mucous membrane of the gums, aphthous stomatitis, very rarely - pancreatitis, hepatitis, abnormal liver function, hepatotoxicity.
On the part of the respiratory system: rarely - shortness of breath, bronchospasm.
On the part of the senses: hearing loss: rarely - hearing loss, ringing or tinnitus; visual impairment: infrequently - blurred vision, scotoma, dryness and irritation of the eye, conjunctival swelling and eyelids (allergic origin), amblyopia, very rarely - accommodation paresis, toxic damage to the optic nerve.
From the central and peripheral nervous system: infrequently - headache, dizziness, insomnia, anxiety, nervousness and irritability, psychomotor agitation, drowsiness, depression, very rarely - confusion, hallucinations, aseptic meningitis (more often in patients with autoimmune diseases).
Since the cardiovascular system: infrequently - tachycardia, increased blood pressure; rarely heart failure.
On the part of the urinary system: infrequently - nephrotic syndrome (edema), oliguria, anuria, polyuria, proteinuria, cystitis, urine staining in red; rarely - acute renal failure, allergic nephritis.
Allergic reactions: infrequently - skin rash (usually erythematous or urticaria), pruritus, very rarely - angioedema, anaphylactoid reactions, anaphylactic shock, bronchospasm or dyspnea, fever, erythema multiforme erythema (including Symptom Symptom, Symptom Symptom, including a syndrome, Symptom Symptom, a symptom of a syndrome, and a Symptomatic syndrome. epidermal necrolysis (Lyell's syndrome), allergic rhinitis.
On the part of the blood-forming organs: infrequently - thrombocytopenia and thrombocytopenic purpura, very rarely - anemia (including hemolytic, aplastic), agranulocytosis, leukopenia, eosinophilia.
Other: very rarely - increased or decreased sweating.
From laboratory indicators: bleeding time (may increase), serum glucose concentration (may decrease), creatinine clearance (may decrease), hematocrit or hemoglobin (may decrease), serum creatinine concentration (may increase), hepatic transaminase activity (may increase ).
If taking Spasgan Neo has caused a change in your normal condition, stop taking it and consult a doctor immediately.
With long-term use, it is necessary to control the pattern of peripheral blood and the functional state of the liver and kidneys.
To reduce the risk of adverse events from the gastrointestinal tract, a minimum effective dose should be used. When symptoms of gastropathy appear, close monitoring is shown, including esophagogastroduodenoscopy, a blood test with hemoglobin and hematocrit, and fecal occult blood analysis.
If it is necessary to determine the 17-ketosteroids, Spasgan Neo should be discontinued 48 hours before the study.
During the period of treatment should refrain from taking alcohol.
Impact on the ability to drive
During the period of treatment, the patient should refrain from practicing potentially hazardous activities that require increased concentration and psychomotor speed.
Store at a temperature not higher than 25 ° С.
Terms of sell
You can buy Spasgan Neo without a prescription.